Question | Answer |
Syngeneic HPCs are collected from this source | identical twin |
Describe graft versus tumor effect in HPC transplantation | T lymphocytes in the donor unit attack residual tumor cells in the recipient |
The primary complication of allogeneic HPC transplantation | Graft Versus Host Disease |
Anatomic site of collection for most allogeneic marrow HPC transplants | iliac crests |
Approximate volume of marrow collected for transplant | 1 L |
Cryopreservative used in storage of frozen HPC units | DMSO (dimethylsulfoxide) |
For major ABO incompatible HPC products, this is removed | RBCs |
For minor ABO incompatible HPC products, this is removed | plasma |
Serious medical complications occur in __% of marrow donors | 1% |
Common side effects of DMSO include | garlic breath, nausea, vomiting, diarrhea, chill, and hypertension |
Storage temperature for HPC marrow | room or refrigerated |
Blood count abnormality sometimes associated with G-CSF | thrombocytopenia |
The safe maximum dose per kg body wieight of DMSO is___ mL/kg/day | 1mL/kg/day |
Which takes longer to engraft: A. Allogeneic HPC, pheresis
B. Allogeneic HPC, marrow C. HPC, cord blood | C. HPC, cord blood |
Why are nonmyeloablative HPC transplants performed? | 1. To enhance Graft versus leukemia effect
2. to minimize transplant related morbidity and mortality
3. permits transplantation of older patients
4. also used in non-malignant conditions |
Before an HPC transplant, cellular blood products should be leukoreduced to reduce the risk of: | 1. HLA alloimmunization
2. CMV transmission
3. Febrile reactions |
definition of WBC engraftment after BMT | absolute neutrophil count >0.5×10(9)/L in the first |
definition of platelet engraftment after BMT | platelet count >20×10(9)/L in the first 7 of consecutive days without transfusion support, respectively |